Institute of Oncology Prof. Dr. Ion Chiricuta

facility RO

3

Publications

8,774

Citations

1

Researchers

Publications

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd , José Rodrigues Pereira , Tudor‐Eliade Ciuleanu +16 more

Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

2005 New England Journal of Medicine 5425 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher , Alex Y. Chang , Purvish M. Parikh +8 more

2005 The Lancet 2086 citations

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more

2014 The Lancet 1263 citations

Affiliated Researchers

Tudor‐Eliade Ciuleanu

Institute of Oncology Prof. Dr. Ion Chiricuta

Institution Info

Type: facility
Country: RO
Publications: 3
Citations: 8,774

External Links

Identifiers

ROR: https://ror.org/00nrbsf87